A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis Clinical Trial

Official title:
A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis

Status Withdrawn

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of itacitinib in participants with moderate to severe ulcerative colitis (UC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Colitis
Colitis, Ulcerative
Moderate to Severe Ulcerative Colitis
Ulcer

Clinical Trial Details

NCT number	NCT03627052
Study type	Interventional
Source	Incyte Corporation
Contact
Status	Withdrawn
Phase	Phase 2
Start date	September 20, 2018
Completion date	November 13, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05486104` - Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis	Phase 2
Recruiting	`NCT04879966` - A Cohort Study Comparing IFX to CS for Moderate to Severe UC
Terminated	`NCT02092389` - Fecal Calprotectin Levels, QoL and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo	N/A
Completed	`NCT04700449` - A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)	Phase 2
Completed	`NCT04090411` - A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis	Phase 2